- Home
- INO vs CVM Comparison
INO vs CVM Comparison
Compare INO & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- CVM
- Stock Information
- Founded
- INO 1979
- CVM 1983
- Country
- INO United States
- CVM United States
- Employees
- INO N/A
- CVM N/A
- Industry
- INO Medical/Dental Instruments
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INO Health Care
- CVM Health Care
- Exchange
- INO Nasdaq
- CVM Nasdaq
- Market Cap
- INO 69.3M
- CVM 71.2M
- IPO Year
- INO 1998
- CVM 1987
- Fundamental
- Price
- INO $2.38
- CVM $10.03
- Analyst Decision
- INO Buy
- CVM
- Analyst Count
- INO 5
- CVM 0
- Target Price
- INO $8.80
- CVM N/A
- AVG Volume (30 Days)
- INO 2.7M
- CVM 303.9K
- Earning Date
- INO 11-13-2025
- CVM 08-14-2025
- Dividend Yield
- INO N/A
- CVM N/A
- EPS Growth
- INO N/A
- CVM N/A
- EPS
- INO N/A
- CVM N/A
- Revenue
- INO $182,337.00
- CVM N/A
- Revenue This Year
- INO N/A
- CVM N/A
- Revenue Next Year
- INO $15,775.73
- CVM N/A
- P/E Ratio
- INO N/A
- CVM N/A
- Revenue Growth
- INO N/A
- CVM N/A
- 52 Week Low
- INO $1.30
- CVM $1.98
- 52 Week High
- INO $7.00
- CVM $39.30
- Technical
- Relative Strength Index (RSI)
- INO 55.04
- CVM 52.57
- Support Level
- INO $2.33
- CVM $9.58
- Resistance Level
- INO $2.98
- CVM $12.68
- Average True Range (ATR)
- INO 0.22
- CVM 1.30
- MACD
- INO -0.01
- CVM -0.28
- Stochastic Oscillator
- INO 43.93
- CVM 28.57
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.